Skip Nav Destination
1-1 of 1
Keywords: CYP3A subfamilyClose
Pharmacology (2011) 88 (1-2): 1–9.
Published Online: 25 June 2011
... by simvastatin. In conclusion, the enhanced bioavailability of losartan might be mainly due to inhibition of P-gp in the small intestine and CYP3A subfamily-mediated metabolism of losartan in the small intestine and/or liver and to reduction of the CL/F of losartan by simvastatin. Original Paper Pharmacology...